The Top 5 Biosimilars Articles for the Week of March 11

March 15, 2019

The Center for Biosimilars® recaps the top news for the week of March 11, 2019.

Transcript

Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of March 11.

Number 5: A survey of health plan benefit sponsors representing employers found that most are using prior authorization or step therapy to encourage the use of biosimilars

Number 4: The Trump administration has released its proposed budget for the fiscal year 2020, and contained within it are a variety of proposals that impact biosimilars.

Number 3: Only 49% of prescribers in a recent European Society for Medical Oncology survey report using biosimilars in routine clinical practice.

Number 2: The FDA has issued a new Form 483 to Biocon over its Bangalore facility. The document makes 2 inspection observations that stem from inspections carried out in February 2019.

Number 1: The FDA has approved Pfizer’s trastuzumab biosimilar referencing Herceptin.

Finally, last week, our e-newsletter asked whether you think that concerns about the safety of Janus kinase inhibitors will make treatment for inflammatory diseases with biosimilars of anti—tumor necrosis factor therapies more appealing.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.